Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 286

1.

Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche.

Tsukamoto S, Løvendorf MB, Park J, Salem KZ, Reagan MR, Manier S, Zavidij O, Rahmat M, Huynh D, Takagi S, Kawano Y, Kokubun K, Thrue CA, Nagano K, Petri A, Roccaro AM, Capelletti M, Baron R, Kauppinen S, Ghobrial IM.

Leukemia. 2018 Jun 20. doi: 10.1038/s41375-018-0161-6. [Epub ahead of print]

PMID:
29925904
2.

Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation.

Cheng MP, Pandit A, Antin JH, Walsh SR, Huynh D, Ghobrial IM, Baden LR, Marty FM, Issa NC.

Blood Adv. 2018 Jun 12;2(11):1272-1276. doi: 10.1182/bloodadvances.2018018911. Erratum in: Blood Adv. 2018 Jul 10;2(13):1541.

3.

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.

O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, Burke JN, Harrington CC, Lively KJ, Lyons HF, Munshi NC, Anderson KC, Trippa L, Richardson PG, Raje NS.

Br J Haematol. 2018 Jul;182(2):222-230. doi: 10.1111/bjh.15261. Epub 2018 May 8.

PMID:
29740809
4.

Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.

Manier S, Park J, Capelletti M, Bustoros M, Freeman SS, Ha G, Rhoades J, Liu CJ, Huynh D, Reed SC, Gydush G, Salem KZ, Rotem D, Freymond C, Yosef A, Perilla-Glen A, Garderet L, Van Allen EM, Kumar S, Love JC, Getz G, Adalsteinsson VA, Ghobrial IM.

Nat Commun. 2018 Apr 27;9(1):1691. doi: 10.1038/s41467-018-04001-5.

5.

Current use of monoclonal antibodies in the treatment of multiple myeloma.

Varga C, Maglio M, Ghobrial IM, Richardson PG.

Br J Haematol. 2018 May;181(4):447-459. doi: 10.1111/bjh.15121. Epub 2018 Apr 25. Review.

PMID:
29696629
6.

Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.

Kurdi AT, Glavey SV, Bezman NA, Jhatakia A, Guerriero JL, Manier S, Moschetta M, Mishima Y, Roccaro A, Detappe A, Liu CJ, Sacco A, Huynh D, Tai YT, Robbins MD, Azzi J, Ghobrial IM.

Mol Cancer Ther. 2018 Jul;17(7):1454-1463. doi: 10.1158/1535-7163.MCT-17-0998. Epub 2018 Apr 13.

PMID:
29654064
7.

Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.

Kawano Y, Zavidij O, Park J, Moschetta M, Kokubun K, Mouhieddine TH, Manier S, Mishima Y, Murakami N, Bustoros M, Pistofidis RS, Reidy M, Shen YJ, Rahmat M, Lukyanchykov P, Karreci ES, Tsukamoto S, Shi J, Takagi S, Huynh D, Sacco A, Tai YT, Chesi M, Bergsagel PL, Roccaro AM, Azzi J, Ghobrial IM.

J Clin Invest. 2018 Jun 1;128(6):2487-2499. doi: 10.1172/JCI88169. Epub 2018 May 14.

8.

Targeting MYC in multiple myeloma.

Jovanović KK, Roche-Lestienne C, Ghobrial IM, Facon T, Quesnel B, Manier S.

Leukemia. 2018 Jun;32(6):1295-1306. doi: 10.1038/s41375-018-0036-x. Epub 2018 Feb 22. Review.

PMID:
29467490
9.

Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation.

Takagi S, Tsukamoto S, Park J, Johnson KE, Kawano Y, Moschetta M, Liu CJ, Mishima Y, Kokubun K, Manier S, Salem KZ, Huynh D, Sacco A, Forward J, Roccaro AM, Battinelli EM, Ghobrial IM.

Clin Cancer Res. 2018 May 15;24(10):2430-2439. doi: 10.1158/1078-0432.CCR-17-2003. Epub 2018 Feb 9.

PMID:
29440174
10.

The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Ghobrial IM, Detappe A, Anderson KC, Steensma DP.

Nat Rev Clin Oncol. 2018 Apr;15(4):219-233. doi: 10.1038/nrclinonc.2017.197. Epub 2018 Jan 9. Review.

PMID:
29311715
11.

Human regulatory T cells undergo self-inflicted damage via granzyme pathways upon activation.

Sula Karreci E, Eskandari SK, Dotiwala F, Routray SK, Kurdi AT, Assaker JP, Luckyanchykov P, Mihali AB, Maarouf O, Borges TJ, Alkhudhayri A, Patel KR, Radwan A, Ghobrial I, McGrath M, Chandraker A, Riella LV, Elyaman W, Abdi R, Lieberman J, Azzi J.

JCI Insight. 2017 Nov 2;2(21). pii: 91599. doi: 10.1172/jci.insight.91599. [Epub ahead of print]

12.

Copper deficiency, a new triad: anemia, leucopenia, and myeloneuropathy.

Wazir SM, Ghobrial I.

J Community Hosp Intern Med Perspect. 2017 Sep 19;7(4):265-268. doi: 10.1080/20009666.2017.1351289. eCollection 2017 Oct.

13.

Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet-Induced Obesity in Male Mice.

Bornstein S, Moschetta M, Kawano Y, Sacco A, Huynh D, Brooks D, Manier S, Fairfield H, Falank C, Roccaro AM, Nagano K, Baron R, Bouxein M, Vary C, Ghobrial IM, Rosen CJ, Reagan MR.

Endocrinology. 2017 Oct 1;158(10):3369-3385. doi: 10.1210/en.2017-00299.

PMID:
28977604
14.

Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing.

Moschetta M, Kawano Y, Sacco A, Belotti A, Ribolla R, Chiarini M, Giustini V, Bertoli D, Sottini A, Valotti M, Ghidini C, Serana F, Malagola M, Imberti L, Russo D, Montanelli A, Rossi G, Reagan MR, Maiso P, Paiva B, Ghobrial IM, Roccaro AM.

Curr Osteoporos Rep. 2017 Oct;15(5):499-506. doi: 10.1007/s11914-017-0399-3. Review.

PMID:
28889371
15.

Established and Novel Prognostic Biomarkers in Multiple Myeloma.

Bustoros M, Mouhieddine TH, Detappe A, Ghobrial IM.

Am Soc Clin Oncol Educ Book. 2017;37:548-560. doi: 10.14694/EDBK_175175. Review.

16.

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, Pettitt JA, Simic MK, Cheng TL, Morse A, Le LMT, Abi-Hanna D, Kramer I, Falank C, Fairfield H, Ghobrial IM, Baldock PA, Little DG, Kneissel M, Vanderkerken K, Bassett JHD, Williams GR, Oyajobi BO, Hose D, Phan TG, Croucher PI.

Blood. 2017 Jun 29;129(26):3452-3464. doi: 10.1182/blood-2017-03-773341. Epub 2017 May 17.

17.

Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.

Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, Ebright RY, Shi J, Park J, Glavey SV, Devine WG, Liu CJ, Leleu X, Quesnel B, Roche-Lestienne C, Snyder JK, Brown LE, Gray N, Bradner J, Whitesell L, Porco JA Jr, Ghobrial IM.

Sci Transl Med. 2017 May 10;9(389). pii: eaal2668. doi: 10.1126/scitranslmed.aal2668.

18.

Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia.

Gustine JN, Meid K, Dubeau T, Hunter ZR, Xu L, Yang G, Ghobrial IM, Treon SP, Castillo JJ.

Br J Haematol. 2017 Jun;177(5):717-725. doi: 10.1111/bjh.14743. Epub 2017 May 9.

PMID:
28485115
19.

A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation.

Sacco A, Kawano Y, Moschetta M, Zavidij O, Huynh D, Reagan M, Mishima Y, Manier S, Park J, Morgan E, Takagi S, Wong KK, Carrasco R, Ghobrial IM, Roccaro AM.

Am J Hematol. 2017 Aug;92(8):E138-E145. doi: 10.1002/ajh.24778. Epub 2017 Jun 15.

PMID:
28474779
20.

The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions.

Sacco A, Fenotti A, Affò L, Bazzana S, Russo D, Presta M, Malagola M, Anastasia A, Motta M, Patterson CJ, Rossi G, Imberti L, Treon SP, Ghobrial IM, Roccaro AM.

Oncotarget. 2017 May 23;8(21):35435-35444. doi: 10.18632/oncotarget.16130. Review.

Supplemental Content

Loading ...
Support Center